MedPath

Phase I trial of weekly gemcitabine with radiotherapy for unresectable locally advanced biliary tract cancer.

Phase 1
Conditions
Biliary tract cancer
Registration Number
JPRN-UMIN000022562
Lead Sponsor
Sapporo medical university, department of medical oncology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

No previous history of treatment.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Adverse events within two weeks after treatment.
Secondary Outcome Measures
NameTimeMethod
Maximum tolerated dose, toxicity
Âİ Copyright 2025. All Rights Reserved by MedPath